Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

205448-29-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • China Biggest factory Supply High Quality 7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone CAS 205448-29-9

    Cas No: 205448-29-9

  • USD $ 1.0-5.0 / Kilogram

  • 1 Kilogram

  • 1000 Kilogram/Day

  • Leader Biochemical Group
  • Contact Supplier

205448-29-9 Usage

General Description

7-Benzyloxy-6-methoxy-1,4-dihydro-4-quinolinone is a chemical compound with the molecular formula C20H19NO3. It is a quinolinone derivative that contains a benzyl and a methoxy group attached to its structure. The compound has potential pharmacological properties and has been studied for its potential use in drug development. It may have applications in the field of medicinal chemistry and could potentially be used as a building block in the synthesis of various pharmaceutical compounds. Additionally, its unique structure and properties make it an interesting target for further research in the fields of organic and medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 205448-29-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,5,4,4 and 8 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 205448-29:
119 % 10 = 9
So 205448-29-9 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017


1.1 GHS Product identifier

Product name 7-(Benzyloxy)-6-methoxy-4(1H)-quinolinone

1.2 Other means of identification

Product number -
Other names 7-benzyloxy-6-methoxy-coumarin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:205448-29-9 SDS

205448-29-9Relevant articles and documents

Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate

Chen, Tao,Fang, Wei-Rong,Huang, Wei,Li, Yun-Man,Liu, Peng-Fei,Zhuo, Lin-Sheng

, (2020/02/29)

A series of 1,6-naphthyridinone-based MET kinase inhibitors bearing quinoline moiety in block A were designed and synthesized based on the structures of Cabozantinib and our reported compound IV. Extensive SAR and DMPK studies led to the identification of 20j, a potent and orally bioavailable MET kinase inhibitor with favorable kinase selectivity. More importantly, 20j exhibited statistically significant tumor growth inhibition (Tumor growth inhibition/TGI of 131%, 4/6 partial regression/PR) in the U-87 MG xeograft model, which is superior to that of Cabozantinib (TGI of 97%, 2/6 PR), and significantly better than that of compound IV (TGI of 15%, 0/6 PR) at the same dose (12.5 mg/kg). Combined with favorable in vitro potency, kinase selectivity, pharmacokinetic profile and in vivo efficacy, the promising antitumor drug candidate 20j has subsequently advanced into preclinical research.



Paragraph 071, (2019/07/13)

The present disclosure describes carbamate and urea compounds as novel multikinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such multikinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders associated with kinases are also described.

A alkyne generation quinoline derivatives and its preparation and use


Paragraph 0118; 0119, (2017/08/25)

The invention discloses alkynylquinoline derivatives, and a preparation method and application thereof. The acetylenoquinoline derivatives are alkynylquinoline compounds as shown in a general formula I which is described in the specification and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof. The invention also provides the preparation method for the derivatives and relates to inhibition activity of the compounds as shown in the formula I to a variety of protein tyrosine kinases (e.g. C-Met and VEGFR). Thus, the compounds can be used as anticancer drugs for treatment of human cancers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 205448-29-9